RE:Might JNJ bad news be good news for ONCY re: JNJ interest?At Johnson & Johnson our commitment to innovation has paved the way in oncology for more than 30 years. We work every day to get in front of cancer, convening the brightest minds to create, nurture and deliver new approaches to detect, intercept and one day cure this disease. Johnson & Johnson said on Thursday the U.S. Food and Drug Administration had approved its antibody-based therapy for patients with a difficult-to-treat type of blood cancer.
The therapy, Talvey, belongs to a class of treatments called bispecific antibodies designed to bring a cancer cell and an immune cell together so the body’s immune system can kill the cancer.
Talvey will be sold at a list price of $45,000 per month, the company told Reuters, adding the price could vary based on a patient’s weight, prescribed dosing and treatment duration
J&J estimates a pricing range of $270,000 to $360,000 for an average treatment duration of six to eight months.
https://www.jnj.com/oncology